stockrow
Friday 6 November 2026
Export DNTH’s income statement to Excel — free account
Dianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
86.43
3.42
+4.12%
Follow DNTH
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
P/S ratio |
781.65 | 116.48 | 20.88 | 0.00 | — | — | — | — | — | — |
Altman Z-Score |
24.31 | 19.55 | 2.61 | (0.46) | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
14.17 | 18.44 | 19.54 | 9.81 | — | — | — | — | — | — |
P/Operating CF |
(33.87) | (26.46) | (4.98) | (0.65) | — | — | — | — | — | — |
Beneish M-Score |
(4.75) | 8.16 | (4.68) | — | — | — | — | — | — | — |
P/B ratio |
3.23 | 2.06 | 0.35 | 0.00 | — | — | — | — | — | — |
Price to Tangible BV |
3.23 | 2.06 | 0.35 | 0.00 | — | — | — | — | — | — |
EV/Sales |
583.07 | 72.33 | (40.59) | 0.00 | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 2.33 | 2.31 | — | — | — | — | — | — |
EV/Operating CF |
(9.20) | (5.77) | 3.11 | 2.40 | — | — | — | — | — | — |
EV/FCF |
(9.18) | (5.76) | 3.10 | 2.39 | — | — | — | — | — | — |
Quick Ratio |
13.16 | 14.96 | 18.09 | 9.86 | 16.29 | 13.02 | 10.32 | 13.68 | 12.45 | 4.69 |
Current Ratio |
13.32 | 15.22 | 18.43 | 9.97 | 16.63 | 13.26 | 10.62 | 13.95 | 12.68 | 4.71 |
Net Debt/EBITDA |
2.20 | 2.56 | 3.53 | 2.50 | 2.43 | 1.94 | 1.80 | 2.41 | 1.46 | 0.49 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.02 | 0.02 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.80 | 0.92 | 0.85 | 1.02 | 0.84 | 0.85 | 0.74 | 0.73 | 0.63 | 0.67 |
Capex/Depreciation |
0.04 | 0.02 | 0.10 | 0.30 | (0.63) | (0.20) | (1.66) | (8.75) | (5.85) | (23.17) |
Interest Coverage |
— | — | — | (21.22) | (746.92) | (20.90) | (13.38) | (24.49) | (151.39) | (56.86) |
| (38.38%) | (32.60%) | (69.97%) | (44.39%) | (44.94%) | (52.57%) | (53.53%) | (111.28%) | 139.26% | 38.18% | |
| (35.88%) | (30.71%) | (33.18%) | (20.86%) | (40.47%) | (46.38%) | (48.16%) | (54.40%) | (107.92%) | (29.59%) | |
ROIC |
(124.80%) | (82.43%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,217.57%) | 0.00% | 0.00% |
Return on Tangible Assets |
(42.83%) | (32.35%) | (25.92%) | (38.51%) | (40.12%) | (50.49%) | (52.72%) | (39.69%) | (70.57%) | (107.66%) |
Average Days of Receivables |
9.32 | 47.24 | 61.74 | 320.69 | — | — | — | — | — | 0.00 |
Research and Development Expense of Revenue |
7,153.14% | 1,332.88% | 1,162.10% | 457.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
1,686.20% | 400.87% | 642.57% | 105.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1,119.50% | 206.80% | 102.62% | 23.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.23 | 0.36 | 2.83 | 12.66 | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 192.72 | — | — | — | — | — | — |
Earnings Yield |
(9.95%) | (11.93%) | (221.20%) | (495.70%) | — | — | — | — | — | — |
Free Cash Flow Yield |
(8.12%) | (10.78%) | (62.66%) | (509.45%) | — | — | — | — | — | — |
Revenue per Share |
0.05 | 0.19 | 0.55 | 7.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(3.34) | (2.35) | (7.15) | (33.26) | (17.33) | (23.32) | (24.68) | (36.44) | (191.76) | (702.04) |
Capex per Share |
(0.01) | 0.00 | (0.02) | (0.16) | (0.37) | (0.15) | (1.32) | (6.66) | (18.94) | (14.95) |
Free Cash Flow per Share |
(3.35) | (2.35) | (7.17) | (33.42) | (17.70) | (23.47) | (26.01) | (43.11) | (210.70) | (716.99) |
Cash per Share |
10.47 | 8.26 | 33.71 | 86.37 | 51.52 | 54.22 | 62.99 | 124.05 | 444.16 | 488.49 |
Shareholders Equity per Share |
12.78 | 10.58 | 32.77 | 84.27 | 50.28 | 52.42 | 61.03 | 126.73 | (362.77) | (954.19) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
12.78 | 10.58 | 32.77 | 84.27 | 50.28 | 52.42 | 61.03 | 126.73 | (362.77) | (954.19) |
Free Cash Flow |
(129.27) | (78.28) | (36.97) | (29.21) | (60.79) | (64.42) | (60.16) | (49.55) | (24.46) | (6.67) |
Working Capital |
378.71 | 262.45 | 167.82 | 73.81 | 169.83 | 140.10 | 135.73 | 134.90 | 48.36 | 8.53 |
Capital Expenditures |
(0.21) | (0.10) | (0.11) | (0.14) | (1.26) | (0.40) | (3.06) | (7.66) | (2.20) | (0.14) |
Net Current Asset Value |
371.92 | 259.37 | 166.92 | 72.58 | 163.43 | 133.81 | 129.52 | 133.66 | (44.08) | (9.38) |
EV/EBIT |
0.00 | 0.00 | 2.38 | 2.35 | — | — | — | — | — | — |
Capex to Sales |
0.10 | 0.02 | 0.04 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(19.37) | (28.90) | (5.77) | (3.23) | 0.27 | 0.24 | 0.19 | 0.09 | 0.19 | 0.01 |
Cash ROIC |
(14.40%) | (12.47%) | (10.79%) | (19.58%) | (17.39%) | (22.01%) | (20.97%) | (17.19%) | (258.88%) | 153.96% |
Accounts Receivable Turnover |
4.74 | 9.70 | 0.92 | 1.08 | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.43 | 0.64 | 3.06 | 5.94 | — | — | — | — | — | — |
Average Payables |
7.15 | 3.59 | 1.89 | 2.10 | 3.40 | 3.29 | 3.15 | 1.83 | 0.92 | 0.92 |
Average Assets |
452.47 | 276.71 | 131.26 | 136.52 | 175.78 | 161.57 | 159.41 | 105.89 | 32.90 | 32.90 |
Average Common Equity |
422.94 | 260.67 | 62.25 | 64.15 | 158.29 | 142.55 | 143.42 | 51.77 | (25.50) | (25.50) |
Columns are period end dates · fundamentals updated 6 Nov 2026